CLINICAL TRIAL SUMMARY

MDACC Study No:2012-1064 (clinicaltrials.gov NCT No: NCT01794702)
Title:Phase I/II Study of Decitabine (DAC) followed by Clofarabine, Idarubicin, and Cytarabine (CIA) in Acute Leukemia
Principal Investigator:Nitin Jain
Treatment Agent:Clofarabine; Cytarabine; Decitabine; Idarubicin
Study Status:Open
Study Description:The goal of Phase I of this clinical research study is find the highest
tolerable dose of clofarabine that can be given with decitabine, idarubicin,
and cytarabine to patients with acute leukemia.

The goal of Phase II of this study is to learn if decitabine followed by the
combination of clofarabine, idarubicin, and cytarabine can help to control
acute leukemia. The safety of this drug combination will also be studied.

Decitabine and idarubicin are designed to damage the DNA (the genetic material
of cells). This may cause cancer cells to die.

Clofarabine is designed to interfere with the growth and development of cancer
cells.

Cytarabine is designed to insert itself into DNA and stop the DNA from
repairing itself.

Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I/Phase II
Treatment Agents:Clofarabine
Cytarabine
Decitabine
Idarubicin
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:N/A
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Nitin Jain
Dept:Leukemia
For Clinical Trial Enrollment:713-745-6080
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults